Patents by Inventor Eran Eden

Eran Eden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of predicting responsiveness to autologous adoptive cell transfer therapy
    Patent number: 8541185
    Abstract: A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8+CD28?CD152? signature in a sample of the subject, wherein a frequency of TILs having the CD8+CD28?CD152? signature above a predetermined level is indicative of a positive responsiveness to cancer treatment. Other signatures reflecting responsiveness to cancer treatment are also disclosed. In addition, methods of treating cancer based on these signatures are also disclosed.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: September 24, 2013
    Assignees: Technion Research & Development Foundation Limited, Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Kfir Oved, Eran Eden, Martin Akerman, Roy Noy, Michal Besser, Yoram Reiter
  • SIGNATURES AND DETERMINANTS FOR DISTINGUISHING BETWEEN A BACTERIAL AND VIRAL INFECTION AND METHODS OF USE THEREOF
    Publication number: 20110275542
    Abstract: The present invention provides methods of detecting infection using biomarkers.
    Type: Application
    Filed: April 20, 2011
    Publication date: November 10, 2011
    Applicant: MeMed Diagnostics, Ltd.
    Inventors: Eran Eden, Kfir Oved
  • T CELL SUBPOPULATIONS CAPABLE OF TREATING CANCER
    Publication number: 20100310534
    Abstract: A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8+CD28?CD152? signature in a sample of the subject, wherein a frequency of TILs having the CD8+CD28?CD152? signature above a predetermined level is indicative of a positive responsiveness to cancer treatment. Other signatures reflecting responsiveness to cancer treatment are also disclosed. In addition, methods of treating cancer based on these signatures are also disclosed.
    Type: Application
    Filed: September 15, 2008
    Publication date: December 9, 2010
    Inventors: Kfir Oved, Eran Eden, Martin Akerman, Roy Noy, Michal Besser, Yoram Reiter
  • CELL POPULATIONS FOR POLYPEPTIDE ANALYSIS AND USES OF SAME
    Publication number: 20100298166
    Abstract: Nucleic acid construct systems are disclosed. The constructs comprise: (i) a first nucleic acid construct comprising a first nucleic acid sequence encoding a first reporter polypeptide linked to an additional nucleic acid sequence capable of inserting the first nucleic acid construct into a genome of a host cell such that an endogenous polypeptide covalently attached to the first reporter polypeptide is expressed in the cell; and (ii) a second nucleic acid construct comprising a second nucleic acid sequence encoding a second reporter polypeptide, linked to an additional nucleic acid sequence capable of inserting in a non-directed manner the second nucleic acid construct into a genome of a host cell such that an endogenous polypeptide covalently attached to the second reporter polypeptide is expressed in the cell, wherein the first reporter polypeptide and the second reporter polypeptide are distinguishable.
    Type: Application
    Filed: January 22, 2009
    Publication date: November 25, 2010
    Inventors: Uri Alon, Alex Sigal, Ron Milo, Tamar Danon, Ariel Cohen, Naama Geva-Zatorsky, Milana Frenkel-Morgenstern, Lydia Cohen, Natalie Perzov, Eran Eden